Akero Therapeutics (AKRO) Announces Proposed Public Offering of Common Stock

Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today that it has commenced an underwritten public offering of $300.0 million of shares of its common stock. All of the shares in the proposed offering are being offered by Akero. In addition, Akero intends to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

J.P. Morgan, Morgan Stanley and Jefferies are acting as joint book-running managers for the proposed offering.

You May Also Be Interested In

• Winnebago Industries refinances credit facility, extends maturity to 2031
• ZeroStack (ZSTK) files for 54.61M share offering by selling stockholders
• Lazard Global Total Return fund declares $0.1534 monthly distribution